


Science Saves Lives



Carlos Blanco, M.D., Ph.D.
Director, Division of Epidemiology, Services and Prevention Research
National Institute on Drug Abuse



Interactions between Drugs, SUD and COVID

- ***Stress: biopsychosocial***

Nicotine Patch

French researchers reported smokers were less likely to contract COVID-19



- ***Structural Factors***

- ***Access to Treatment Programs***
- ***Access to Peer-support groups***
- ***Isolation***
- ***Access to Community Services***

- ***Social factors***

- ***Stigmatized Disease***
- ***Homelessness***
- ***Criminalization***



Worse COVID outcomes among smokers

Multiple System Changes

- **Changes in Access: Telemedicine**
Remote medical practices (rural)
Virtual support meetings
- **Regulatory changes: Take-home medicines for MOUD**
Changes in buprenorphine induction
Interstate practice
- **Reimbursement changes**
- **Release on non-violent offenders with SUD from jails and prisons, which might improve their long-term outcomes**

Challenges

- Limited evidence-based approach
- Lack of epi and outcome data
- Assessment of emergencies
- Direct observation
- Home office
- Uncertainty and clinicians' anxiety

Opioids and Stimulants: Challenges

- Cocaine and methamphetamine consequences are increasing in the context of mixed evidence for overall population prevalence increases
- **Links to the evolving opioid overdose crisis**
 - Increasing prevalence of stimulant use among those with OUD
 - Since 2008, >300% increase in methamphetamine among heroin treatment admissions
 - 50% of psychostimulant-related overdose deaths involved opioids (2017)
- **People using stimulants have**
 - High rates of co-occurring mental illness
 - Poly-substance use is common (*including nearly universal prior use of cigarettes, alcohol, cannabis*)
- No FDA approved medications for treatment (“MOUD”) or rescue (“naloxone”)
- Contingency management is time consuming and difficult to access

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus Notice Number: NOT-DA-20-047

- Key Dates

Release Date: March 19, 2020

First Available Due Date: March 19, 2020

Expiration Date: March 31, 2021

- Related Announcements

[PA-18-935](#) Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)

[PA-18-591](#) Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

- Issued by

National Institute on Drug Abuse ([NIDA](#))

- Purpose


- NIDA is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 Novel Coronavirus (2019-nCoV, also known as COVID-19). NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from SUD.

A New Way of Doing Science

- Using *Clinical Practice/Public Health Needs* to *Generate Research Questions*
- Ensuring that *Research Findings are Applied to Practice*




Traditional View of Science: Top Down




Rogers, 1962

Dialogue and Iteration



Greene et al., Ann Int Med, 2012

Science Saves Lives



Carlos Blanco, M.D., Ph.D.
Director, Division of Epidemiology, Services and Prevention Research
National Institute on Drug Abuse

